Module 5 - Monitoring and Managing Adverse Events with Antibody-Drug Conjugates: Part 1 (4 minute video)

This module examines key adverse events associated with antibody-drug conjugates, including neutropenia, anemia, thrombocytopenia, and gastrointestinal (GI) toxicity.

David B. Page, MD

Medical Oncologist
Clinical Investigator
Providence Cancer Institute

Dr. David Page is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy.

He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.

He has conducted and published outcomes of numerous investigator-initiated trials, including trials combining immune checkpoint blockade with chemotherapy, radiotherapy, and novel targeted/immune therapies in breast cancer, both in the curative and metastatic setting. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunofluorescence working group.

1.
DEVELOP a plan to monitor for and manage AEs in patients with breast cancer treated with ADCs, in order to avoid interruptions in care